Sorafenib therapy in patients with advanced hepatocellular carcinoma in liver cirrhosis: a single center experience

Background: Sorafenib has become the treatment standard for patients with advanced hepatocellular carcinoma (HCC). However, it is not clear whether patients with impaired liver function (Stadium Child-Pugh B) in liver cirrhosis and patients undergoing additional locoregional therapy may benefit from and tolerate the treatment with sorafenib Aim: We evaluated the tolerability and efficacy of sorafenib in patients with advanced HCC and liver cirrhosis, in some cases in combination with a locoregional therapy. Methods: 50 patients with advanced HCC were treated with sorafenib. Tolerability and efficacy of the thera…